[go: up one dir, main page]

MX2009009862A - Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico. - Google Patents

Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico.

Info

Publication number
MX2009009862A
MX2009009862A MX2009009862A MX2009009862A MX2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A MX 2009009862 A MX2009009862 A MX 2009009862A
Authority
MX
Mexico
Prior art keywords
core
byweight
active principle
withrespect
amounts
Prior art date
Application number
MX2009009862A
Other languages
English (en)
Inventor
Stefano De Luigi Bruschi
Matteo Cerea
Andrea Gazzaniga
Maria Edvige Sangalli
Lucia Zema
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MX2009009862A publication Critical patent/MX2009009862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma de dosificación de liberación prolongada/pulsátil en un tiempo específico que comprende; • un núcleo que comprende al menos un principio activo y al menos un agente desintegrante; • una capa selladora que rodea el núcleo que esencialmente consiste de uno o más polímeros independientes de pH insolubles o solubles en agua; • un revestimiento exterior esencialmente que consiste de uno o más polímeros independientes de pH; en donde: al menos un agente desintegrante es presente en cantidades de 1-20% por peso y al menos un principio activo es presente en cantidades de 1-80% por peso, con relación al núcleo; la capa selladora se representa en 0.1-10% por peso, con relación al núcleo; el revestimiento exterior se representa en 5-500% por peso, con relación al núcleo. Estos núcleos cubiertos son capaces de asegurar la liberación inmediata del principio activo después de un intervalo de tiempo pre-definido, independientemente de las variaciones de pH fisiológicas que ocurren en el tracto gastrointestinal de los mamíferos.
MX2009009862A 2007-03-15 2008-03-12 Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico. MX2009009862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104213A EP1970056A1 (en) 2007-03-15 2007-03-15 Time-specific delayed/pulsatile release dosage forms
PCT/EP2008/052957 WO2008110577A1 (en) 2007-03-15 2008-03-12 Time- specific delayed/pulsatile release dosage forms

Publications (1)

Publication Number Publication Date
MX2009009862A true MX2009009862A (es) 2009-12-14

Family

ID=38063792

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009862A MX2009009862A (es) 2007-03-15 2008-03-12 Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico.

Country Status (11)

Country Link
US (1) US20100028426A1 (es)
EP (2) EP1970056A1 (es)
JP (1) JP2010521437A (es)
KR (1) KR20090119986A (es)
CN (1) CN101636153A (es)
AR (1) AR065778A1 (es)
BR (1) BRPI0808801A2 (es)
CA (1) CA2679210A1 (es)
MX (1) MX2009009862A (es)
RU (1) RU2452472C2 (es)
WO (1) WO2008110577A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
WO2010064100A1 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Baclofen gastroretentive drug delivery system
US20120039954A1 (en) * 2008-12-15 2012-02-16 Somnus Therapeutics, Inc. Method of treating insomnia
CN103816130B (zh) * 2014-01-22 2016-01-20 悦康药业集团有限公司 一种盐酸二甲双胍缓释片
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
IT202000011050A1 (it) * 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
ES2106818T3 (es) * 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
AU3949093A (en) * 1992-03-31 1993-11-08 Benzon Pharma A/S A pharmaceutical formulation
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
PT1206248E (pt) * 1999-08-26 2003-11-28 Neurocrine Biosciences Inc Composicoes sedativo-hipnoticas de libertacao controlada e metodos relacionados com os mesmos
WO2001080824A2 (en) * 2000-04-19 2001-11-01 Eurand America, Inc. Dual mechanism timed release dosage forms for low dose drugs
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
WO2003103637A2 (en) * 2002-01-10 2003-12-18 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
EP1689367A1 (en) * 2003-10-21 2006-08-16 Actavis Group HF Pharmaceutical formulations containing quetiapine
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
CA2588215A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006228525A1 (en) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
BRPI0609598A2 (pt) * 2005-03-29 2010-04-20 Roehm Gmbh forma farmacêutica multiparticulada compreendendo péletes com uma substáncia possuindo um efeito modular em relação à liberação de ingrediente ativo
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system

Also Published As

Publication number Publication date
BRPI0808801A2 (pt) 2014-08-19
RU2009138048A (ru) 2011-04-20
KR20090119986A (ko) 2009-11-23
RU2452472C2 (ru) 2012-06-10
AR065778A1 (es) 2009-07-01
JP2010521437A (ja) 2010-06-24
EP2120888A1 (en) 2009-11-25
CA2679210A1 (en) 2008-09-18
CN101636153A (zh) 2010-01-27
WO2008110577A1 (en) 2008-09-18
EP1970056A1 (en) 2008-09-17
US20100028426A1 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
JP6804790B1 (ja) Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
MX2009009862A (es) Formas de dosificacion de liberacion prolongada/pulsatil en un tiempo especifico.
EP2755648B1 (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2008267058C1 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US20080317807A1 (en) Strontium fortified calcium nano-and microparticle compositions and methods of making and using thereof
CN107406421A (zh) sGC刺激物
WO2009082459A3 (en) Anti-aging composition containing resveratrol and method of administration
JP2008280351A5 (es)
ME00181B (me) Farmaceutske formulacije inhibitora renin-angiotenzin sistema (ras) i njihova primjena
RU99126869A (ru) Фармацевтический препарат омепразола
EP3248602A1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
WO2008085484A3 (en) Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
JP7016853B2 (ja) ｓＧＣ刺激剤のリンプロドラッグ
HK1198288A1 (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
JP2008534592A5 (es)
WO2008002567A3 (en) Methods of treating conditions by sustained release administration of benzimidazole derivatives
CN101259113B (zh) 依托度酸渗透泵型控释制剂
CN104586771B (zh) 一种盐酸坦洛新缓释微丸制剂
CN101011393B (zh) 厄贝沙坦胃内滞留型缓释药物组合物
CN101098867A (zh) 取代的亚砜类化合物和其制备方法及用途
WO2009008004A3 (en) Sustained release formulations of divalproex sodium
CN103142537B (zh) 骨化三醇缓释剂片
CN103520136A (zh) 孟鲁斯特钠脉冲胶囊及其制备方法
CN104324377B (zh) 一种复方降压制剂及其应用

Legal Events

Date Code Title Description
FA Abandonment or withdrawal